Guggenheim Rates Johnson & Johnson (JNJ) buy, $270 Price Target

Guggenheim maintains its buy rating on Johnson & Johnson, setting a price target of $270, a 4.44% upside from the current price.

By EarningsIQ Research Desk · Published Jun 26, 2026, 11:02 AM EDT · Updated Jun 30, 2026, 1:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Guggenheim rated Johnson & Johnson ($JNJ) "buy" with a $270 price target on June 26, 2026.

Since the rating, $JNJ is up 1.8% after 1 week, up 4.4% after 1 month and up 0.8% to date (from the $253.41 close on Jun 26, 2026).

JNJ Johnson & Johnson

$255.56 +25.23% year to date

Daily close · Oct 16, 2026

Key Points

Guggenheim reiterated its buy rating on Johnson & Johnson, setting a price target of $270 on June 26, 2026.
Guggenheim's $270 price target implies 4.44% upside from Johnson & Johnson's ($JNJ) current $258.51 share price.
Johnson & Johnson shares traded at $244.88 on Friday, with a market cap of $589.5 billion and a P/E ratio of 28.41.
Insiders at Johnson & Johnson have been active, with recent transactions including both purchases and sales.

Get $JNJ trade alerts by text

We text you when insiders, Congress or big funds trade $JNJ. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Johnson & Johnson alert may contain errors. Disclosures

Guggenheim reiterated its buy rating on Johnson & Johnson (NYSE:JNJ) on June 26, 2026, maintaining its price target at $270. Analyst Vamil Divan continues to express confidence in the company's prospects.

Johnson & Johnson Stock Up 1.8%

Shares of NYSE:JNJ traded near $244.88 on Friday. Johnson & Johnson boasts a market cap of about $589.5 billion and a P/E ratio of 28.41. The stock's 52-week range spans from $151.01 to $251.71, with a 50-day moving average of $230.34 and a 200-day moving average of $216.95. Its beta of 0.256 suggests lower volatility compared to the market.

12-month forecast

$JNJ price target

Johnson & Johnson daily closes and this analyst's $270 target. Not advice.

Recent Earnings

Johnson & Johnson reported revenues of approximately $96.36 billion, with a revenue growth of 9.9%. The company achieved a net margin of 21.83% and a return on equity of 26.42%. Its earnings per share stand at $8.62. The next earnings release is scheduled for July 15, 2026.

Dividend

Johnson & Johnson pays an annual dividend of $5.36 per share, yielding 2.19%. The dividend payout ratio is 60.25%, providing a steady income stream for investors.

Insider Buying and Selling at Johnson & Johnson

Insiders at Johnson & Johnson have been active recently. On June 11, 2026, Kathryn Wengel, EVP and Chief TO and Risk Officer, sold 10,000 shares at an average price of $241.15. On the same day, she also bought 10,000 shares at $115.67. Other insiders, including Marillyn Hewson, Eugene Woods, and Daniel Pinto, made smaller purchases on June 9, 2026, at $232.79 per share.

Analysts Set New Price Targets

On June 26, 2026, Guggenheim maintained its buy rating on Johnson & Johnson with a $270 price target. Previously, on May 13, 2026, Leerink Partners upgraded the stock to a buy with a $265 target. Barclays and Stifel both maintained their hold ratings in April 2026, with targets of $255 and $250, respectively. The consensus recommendation is a buy, with an average target price of $257.32 among 22 analysts.

About Johnson & Johnson

Johnson & Johnson, headquartered in New Brunswick, New Jersey, is a global healthcare company. It operates through two segments: Innovative Medicine and MedTech. The company develops and sells a wide range of healthcare products, including pharmaceuticals, medical devices, and consumer health products. Led by CEO Joaquin Duato, Johnson & Johnson employs over 138,200 people worldwide.

Bottom Line

Guggenheim's reiteration of a buy rating with a $270 target reflects continued optimism in Johnson & Johnson's performance. As a major player in the healthcare sector, the company remains under close watch by investors. This analyst update is part of the regular reviews that can influence investor sentiment, though it's important to remember that such ratings are based on past performance and projections.